News from Wednesday, August 6, 2025
Articles
Aflibercept 8mg Noninferior to Aflibercept 2mg in Diabetic Macular Edema
(8/5, Ryan Livingston, HCPLive) reports “Aflibercept 8mg showed noninferior BCVA improvements compared to 2mg in DME secondary to RVO, with fewer injections required. The QUASAR study involved 892 patients and used a randomized, double-blind, active-controlled design over 64 weeks.” Full
Immune Checkpoint Inhibitors More Effective vs Bevacizumab in Nonsquamous NSCLC
(8/6, Julia Bonavitacola, The American Journal of Managed Care) reports “...The efficacy of immune checkpoint inhibitors (ICIs) combined with chemotherapy was high in advanced driver gene–negative nonsquamous non–small cell lung cancer (NS-NSCLC) when tested against bevacizumab combined with chemotherapy, according to a new study published in Journal of Multidisciplinary Healthcare. The use of ICIs also had less impact on immune function in patients using the treatment.” Full
England: Pharma Firms To Benefit From Parallel HTA & Regulatory Pathway
(8/6, Eliza Slawther, Pink Sheet) reports “...The UK drug regulator and England’s health technology assessment agency have joined forces under an information sharing agreement, aimed at accelerating patient access to newly approved medicines by three to six months.” Subscription Required
Press Releases
NICE Approves First Immunotherapy Combination for Endometrial Cancer
(8/6, NICE Press Release) “Around 2,100 people with advanced womb cancer are set to benefit from a groundbreaking new treatment option, following our recommendation of pembrolizumab (Keytruda) in final draft guidance published today.” Full
Journals
Comparison of the Efficacy of Immune Checkpoint Inhibitors Combined with Chemotherapy Versus Bevacizumab Combined with Chemotherapy in Advanced Driver Gene-Negative Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Study
Chen W, et al.
July 29, 2025, Journal of Multidisciplinary Healthcare
Journal of Multidisciplinary Healthcare
Comparative Effectiveness of Management Strategies for Stage IV Prostate Cancer: A Narrative Review
Okelue E. Okobi, et al.
August 5, 2025, Cureus
Comparison of the Safety and Efficacy Between Endovenous Laser Ablation and Radiofrequency Ablation for Great Saphenous Vein Incompetence
Xianhao Su, et al.
August 5, 2025, Phlebology: The Journal of Venous Disease
Phlebology: The Journal of Venous Disease
Excimer Laser Ablation combined with Drug-Coated Balloon for De Novo Atherosclerotic Lesions in Lower Extremities
Xiaolang Jiang, et al.
August 5, 2025, medRxiv
Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician's Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma
Cyrille Touzeau, et al.
August 6, 2025, Advances in Therapy
Access in All Areas? A Round up of Developments in Market Access and Health Technology Assessment: Part 9
Sreeram V Ramagopalan, Annie Jullien Pannelay
August 6, 2025, Journal of Comparative Effectiveness Research
Journal of Comparative Effectiveness Research
Clinical Performance and Cost-Effectiveness of Low-Shrinkage Giomer Resin Composite Versus Resin-Modified Glass Ionomer in Cervical Carious Lesions: A 12-Month Randomized Controlled Trial
Menna El Ghamrawy, et al.
August 6, 2025, BMC Oral Health